Intravenous Immunoglobulin (IVIg)
  • Proposed mechanism of action is antagonization of fas-fas ligand activity
  • No controlled studies have been performed with current evidence conflicted on its efficacy
  • A summary of current evidence has been produced by French et al
  • Despite this the use of IVIg is considered as a ‘Red’ indication for short term use by the department of Health Guidelines - considered the highest priority because of a risk to life without treatment
Ciclosporin
  • Proposed mechanism of action is suppressant of T-cell function reducing keratinocyte apoptosis
  • Data is scarce and of poor quality limiting recommendations